KARAKTERISTIK PASIEN LIMFOMA YANG DILAKUKAN PEMERIKSAAN IMUNOHISTOKIMIA CD20 DI LABORATORIUM PATOLOGI ANATOMI RSUD ABDUL WAHAB SJAHRANIE SAMARINDA PERIODE 2017–2020

  • Mutmainnah Mutmainnah Program Studi Kedokteran, Fakultas Kedokteran Universitas Mulawarman Samarinda
  • Hadi Irawiraman Laboratorium Patologi Anatomi Fakultas Kedokteran Universitas Mulawarman, Samarinda
  • Moriko Pratiningrum Laboratorium Telinga Hidung Tenggorokan – Kepala Leher, Fakultas Kedokteran Universitas Mulawarman, Samarinda
Keywords: Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Immunohistochemistry CD20 Treatment

Abstract

Lymphoma is a malignant, deadly cancer and many people from developed and developing countries may be still diagnosed with it. The location and subtype of lymphoma cancer will determine the management and prognosis among lymphoma patients. Due to the different management and prognosis of lymphoma, immunohistochemistry CD20 (Cluster of Differentiation 20) is required to help diagnose Non-Hodgkin lymphoma or Hodgkin lymphoma. This study is aimed at finding the characteristics of lymphoma patients treated with immunohistochemistry CD20 at the Anatomic Pathology Laboratory Abdul Wahab Sjahranie Regional Public Hospital, Samarinda from 2017 to 2020. This was a descriptive study applying cross sectional approach. The data were patient’s medical records obtained at Abdul Wahab Sjahranie Regional Public Hospital, Samarinda. There were 205 patients fulfilling the inclusion criteria. The results of the study on lymphoma patients who treated with CD20 immunohistochemical examination showed that the incidence of lymphoma in 2017 was 30.7% (n=63), in 2018 it was 33.2% (n=68), in 2019 it was 20% (n=41) and in 2020, namely 16.1% (n=33), lymphoma patients who treated with immunohistochemical examination of CD20 were 61.2% (n=205) and without CD20 were 38.8% (n=130), lymphoma in men was 62, 4% (n=128) and women 37.6% (n=77), the highest age group was 46-65 years as much as 45.4% (n=93), the most lymphoma locations were lymphoma nodal colli, it was 40.5% (n=83) and abdominal extranodal lymphoma was 22.9% (n=47), the results of immunohistochemical CD20+ were 86.8% (n=178) and CD20- was 13.2% (n=27), the type of lymphoma in Non-Hodgkin's lymphoma was 91.2% (n=187) with the most subtype DLBCL 72.2% (n=148) and Hodgkin's lymphoma was 8.8% (n=18) with the most subtype Nodular Sclerosis 5.9% (n=12). Based on this study, it can be concluded that the incidence of lymphoma who treated with CD20 immunohistochemical examination for the period 2017-2020 was 205 patients, the highest number of lymphoma patients was in men, age group 46-65 years, lymphoma nodal colli, type of Non-Hodgkin's Lymphoma with subtype DLBCL.

References

Adiputra, P. (2020). Dampak Pandemi COVID-19 pada Pelayanan Pasien Kanker di Rumah Sakit Tersier di Indonesia: Serial Kasus. Jurnal Bedah Nasional, 4(1), S29-S33.

Ansell, S. (2015). Hodgkin Lymphoma: Diagnosis and Treatment. National Library of Medicine, 90(11):1574-83.

Asmara, I. (2018). Penanda Biologis Limfoma Maligna. Jurnal Kedokteran Universitas Mataram, 7 (4): 40-48.

Bakta, I. (2007). Hematologi Klinik Ringkas. Jakarta: EGC.

Bispo, J. B., Pinheiro, P. S., & Kobetz, E. K. (2020). Epidemiology and Etiology of Leukemia and Lymphoma. Cold Spring Harbor Perspectives in Medicine, 10(6):a034819.

Bracci, P., & Holly, E. (2005). Tobacco use and non-Hodgkin lymphoma: results from a population-based case-control study in the San Francisco Bay Area, California . National Library of Medicine, 16(4):333-46.

Dwianingsih, E. K., Indrawati, Hardianti, M. S., Malueka, R. G., Iswar, R. R., Sutapa, S. A., & Triningsih, E. F. (2016). Histopathological Features of Lymphoma in Yogyakarta, Indonesia. National Library of Medicine, 17(9):4213-4216.

Fadli, M., Norahmawati, E., Yudhanto, H., & Al Rasyid, H. (2019). Perbedaan Antara Ekspresi CD3, CD20, CD43 Limfoma Non-Hodgkin Sel B. Majalah Kesehatan Fakultas Kedokteran Universitas Brawijaya, Vol 6, No 4.

Fisher, S., & Fisher, R. (2004). The epidemiology of non-Hodgkin's lymphoma . National Library of Medicine, 23(38):6524-34.

GLOBOCAN. (2018). GLOBOCAN 2018 World. World Health Organization International Agency for Research on Cancer, https://gco.iarc.fr.

Gui, L., Han, X., He, X., Song, Y., Yao, J., Yang, J., . . . Shi, Y. (2016). Phase I Study of Chimeric Anti-CD20 Monoclonal Antibody in Chinese Patients with CD20-Positive non-Hodgkin’s Lymphoma. National Library of Medicine, 28(2):197-208.

Hoffbrand, A., & Moss, P. (2016). Hoffbrand’s Essential Haematology Seventh Edition. UK: John Wiley & Sons Ltd.

Kashyap, R., Mittal, B., Manohar, K., Harisankar, C., Bhattacharya, A., Singh, B., . . . Varma, S. (2011). Extranodal manifestations of lymphoma on [18F]FDG-PET/CT: a pictorial essay. Cancer imaging : the official publication of the International Cancer Imaging Society, 11(1), 166–174.

Kemenkes RI. (2015). Data dan Kondisi Penyakit Limfoma di Indonesia. Jakarta Selatan: Kementerian Kesehatan Republik Indonesia Pusat Data dan Informasi.

Kumar, V., Abbas, A., & Aster, J. (2013). Robbins Basic Pathology 9th Ed. Philadelphia: W. B. Saunders Company.

Kumar, V., Abbas, A., & Aster, J. (2015). Buku Ajar Patologi Robbins Edisi 9. Singapura: Elsevier Saunders.

Kumar, V., Abbas, A., & Aster, J. (2018). Buku Ajar Patologi Robbins Edisi 10. Singapura: Elsevier Saunders.

Lash, B. (2020). Hodgkin Lymphoma: Practice Essentials, Background, Pathophysiology [Internet]. Medscape, https://emedicine.medscape.com/article/201886-overview.

Medeiros, L., & Miranda, R. (2018). Diagnostic Pathology: Lymph Nodes and Extranodal Lymphomas, Second Edition. Philadelphia: Elsevier.

Mohamed, O., Bastawisy, A., Allahlob, N., Abdellateif, M., Zekri, A., Shaarawy, S., . . . Bahnassy, A. (2020). The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt. National Library of Medicine, 15(1):10.

Morton, L., Turner, J., Cerhan, J., Linet, M., Treseler, P., Clarke, C., . . . Weisenburger, D. (2007). Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) . National Library of Medicine, 110(2):695-708.

Mozaheb, Z. (2012). Epidemiology of Lymphoid Malignancy in Asia. intechopen, DOI: 10.5772/31746.

Mushtaq, S., Akhtar, N., Jamal, S., Mamoon, N., Khadim, T., Sarfaraz, T., & Waqar, A. (2008). Malignant Lymphomas in Pakistan According to WHO Classification of Lymphoid Neoplasms. National Library of Medicine, 9(2):229-32.

Paramartha, I., & Rena, R. (2017). Karakteristik Pasien Limfoma Maligna di RSUP SANGLAH Tahun 2015. E-Jurnal Medika, 6(2).

Poppe, H., Kerstan, A., Böckers, M., Goebele, M., Geissinger, E., Rosenwald, A., & Hamm, H. (2015). Childhood mycosis fungoides with a CD8+ CD56+ cytotoxic immunophenotype . National Library of Medicine, 42(4):258-64.

Reksodiputro, A. (2015). Multicentre Epidemiology and Survival Study of B Cell Non Hodgkin Lymphoma Patients In Indonesia. Journal of Blood Disorders & Transfusion, 6(2):2-6.

Reykaningrum, A. (2014). DETERMINAN KEJADIAN KANKER KELENJAR GETAH BENING di RSD dr. SOEBANDI JEMBER. Repository Universitas Jember.

Saini, K. S., Azim Jr, H. A., Cocorocchio, E., Vanazzi, A., Saini, M. L., Raviele, P. R., . . . Peccatori, F. A. (2011). Rituximab in Hodgkin lymphoma: is the target always a hit? National Library of Medicine, 37(5):385-90.

Sergentanis, T., Kanavidis, P., Michelakos, T., & Petridou, E. (2013). Cigarette smoking and risk of lymphoma in adults: a comprehensive meta-analysis on Hodgkin and non-Hodgkin disease. European Journal of Cancer Prevention, 22(2), 131–150.

Shahid, R., Gulzar, R., Avesi, L., Hassan, S., Danish, F., & Mirza, T. (2016). Immunohistochemical Profile of Hodgkin and Non-Hodgkin Lymphoma . National Library of Medicine, 26(2):103-7.

Smith, A., Crouch, S., Lax, S., Li, J., Painter, D., Howell, D., . . . Roman, E. (2015). Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. British Journal of Cancer, 112, 1575–1584.

Soetandyo, N., Rebecca, R., Yunti, M., & Reksodiputro, A. (2018). Limfoma Komposit: Limfoma Hodgkin dan Limfoma Non-Hodgkin. Jurnal Penyakit Dalam Indonesia, 5: 3.

Wibawa, I., & Ekawati, N. (2020). KARAKTERISTIK PASIEN LIMFOMA MALIGNA DI RUMAH SAKIT UMUM PUSAT SANGLAH DENPASAR BALI TAHUN 2018. Jurnal Medika Udayana, 10(1), 47-52.

Yavasoglu, I., Sargin, G., Kadikoylu, G., Doger, F., & Bolaman, Z. (2015). Immunohistochemical Evaluation of CD20 Expression in Patients with Multiple Myeloma. National Library of Medicine, 37(1):34-7.

Zhou, L., Deng, Y., Li, N., Zheng, Y., Tian, T., Zhai, Z., . . . Dai, Z. (2019). Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study. Journal of Hematology and Oncology, 12:107.

Published
2022-05-18
Section
Articles
Abstract = 105 times
PDF downloaded = 187 times